EVIDENCE-BASED THERAPY FOR PEPTIC ULCER DISEASE

Abstract

Helicobacter pylori infection and the administration of non-steroidal anti-inflammatory drugs (NSAIDs) are implicated as the primary etiopathogenetic contributors to peptic ulcers. Therefore, H. pylori eradication or cessation of NSAID administration is the primary therapeutic strategy against peptic ulcers. Acid suppressants including proton pump inhibitors are also used to treat peptic ulcer disease. An increasing number of patients are being prescribed antithrombotic therapy in Japan in recent times; therefore, it is important to focus on prevention of upper gastrointestinal bleeding in this patient population. The clinical research findings in this field should be used as guidelines in real-world practice. Currently, an increasing number of patients are being diagnosed with idiopathic peptic ulcers; therefore, it is important to focus on the clinical management of this condition.